Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 27.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,827 shares of the biotechnology company’s stock after buying an additional 613 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Sarepta Therapeutics were worth $353,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Mather Group LLC. acquired a new stake in Sarepta Therapeutics during the first quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. boosted its holdings in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter valued at $31,000. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics in the first quarter valued at $32,000. Finally, GAMMA Investing LLC lifted its position in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Jefferies Financial Group began coverage on Sarepta Therapeutics in a report on Monday. They issued a “buy” rating and a $165.00 price target for the company. Citigroup lowered their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $152.00 price target on shares of Sarepta Therapeutics in a report on Friday, September 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 14th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the company’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Up 0.9 %

Shares of NASDAQ:SRPT opened at $128.42 on Wednesday. The company has a 50 day moving average of $128.87 and a two-hundred day moving average of $132.42. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $12.14 billion, a price-to-earnings ratio of 1,167.45 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the company posted ($0.27) EPS. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.